Summary

The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Neuroimaging Software refers to specialized medical software used to process, quantify, visualize, interpret, and manage analytical outputs derived from imaging of the brain and central nervous system. The market primarily covers software applied to MRI and its advanced sequences, CT/CTA/CTP, PET, SPECT, and multimodal neuroimaging datasets. Core capabilities include image registration and correction, automated tissue and lesion segmentation, brain volumetry and morphometry, perfusion analysis, diffusion and tractography processing, functional brain mapping, molecular imaging quantification, longitudinal change assessment, AI-assisted abnormality detection, and structured reporting. Commercial products are delivered through on-premise workstations, server-based applications, cloud or SaaS platforms, identifiable advanced post-processing modules integrated into imaging environments, and specialized analytical platforms supporting clinical trials and neuroscience research. Neuroimaging Software is primarily used in stroke and cerebrovascular disease, Alzheimer’s disease and other neurodegenerative disorders, multiple sclerosis, neuro-oncology, epilepsy, neurosurgical planning, functional brain assessment, and CNS drug development. The market is characterized by a combination of regulated clinical software, specialized quantitative imaging tools, AI-enabled decision-support applications, and research-oriented commercial platforms.
Key Findings
Europe has the densest specialist supplier base, while North America combines major imaging platforms with leading neurovascular and surgical-planning vendors
Stroke and cerebrovascular imaging remain commercially established applications, while neurodegenerative monitoring is becoming a more important source of incremental demand
MRI-based quantification is expanding from diagnostic assessment toward treatment eligibility, longitudinal monitoring and ARIA evaluation
Market Trends
Neuroimaging Software is shifting from isolated post-processing tools and single-purpose algorithms toward integrated, multimodal and longitudinal analytical workflows. MRI remains central to quantitative brain analysis, while CT-based stroke applications, PET and SPECT quantification, diffusion imaging, functional MRI and multimodal fusion broaden the addressable clinical workflows. Product development is increasingly focused on automated segmentation, quantitative biomarkers, longitudinal comparison, structured reporting and cloud-enabled delivery rather than stand-alone visualization alone. The expansion of disease-modifying therapies for Alzheimer’s disease is also strengthening the role of quantitative MRI and treatment-safety monitoring. In August 2025, the U.S. FDA required an additional earlier MRI monitoring point for patients receiving lecanemab because of ARIA risk, reinforcing the importance of repeatable brain-image assessment during therapy. At the same time, consolidation is accelerating as larger imaging and digital-health groups acquire specialized analytical technologies: GE HealthCare completed its acquisition of icometrix in 2025, SyntheticMR completed its acquisition of Combinostics, and RadNet acquired Gleamer for integration into DeepHealth in March 2026.
Market Dynamics
Drivers
Demand for Neuroimaging Software is being supported by the rising clinical need for faster and more standardized interpretation of complex neurological imaging, together with increasing use of quantitative biomarkers in stroke, dementia, multiple sclerosis, neuro-oncology and neurosurgical planning. Hospital systems are seeking tools that reduce manual measurement, improve consistency across readers and accelerate time-sensitive workflows, particularly in acute stroke. Another important driver is the growing role of imaging in treatment selection and safety monitoring for neurodegenerative therapies. FDA requirements for additional MRI monitoring during lecanemab therapy illustrate how imaging is becoming more closely connected to longitudinal therapeutic management rather than one-time diagnosis alone. CNS drug development also creates demand for standardized MRI and PET analysis across sites and time points, supporting specialized clinical-trial imaging and biomarker platforms.
Restraints
Market adoption remains constrained by fragmented reimbursement, lengthy hospital procurement cycles, regulatory requirements, interoperability issues and the cost of integrating analytical software into existing radiology and clinical workflows. Neuroimaging algorithms must also perform consistently across scanners, protocols, patient populations and imaging quality levels, increasing the cost of validation and product maintenance. In research-oriented applications, widely used academic and open-source software continues to limit pricing power for commercial vendors. Large imaging OEMs can also bundle advanced post-processing functions into broader workstation or enterprise-imaging contracts, which can reduce the addressable stand-alone software value for independent suppliers. These factors mean that technically strong products do not automatically translate into rapid commercial adoption, particularly where the clinical workflow benefit or reimbursement pathway is not clearly defined.
Opportunities
The most attractive opportunities are emerging where Neuroimaging Software moves beyond image visualization to support treatment pathways, measurable biomarkers and longitudinal disease management. Quantitative MRI for Alzheimer’s disease, ARIA assessment, automated brain volumetry, multiple-sclerosis monitoring, PET-based neurodegenerative biomarkers and treatment-response analysis are becoming increasingly relevant. CMS documentation on automated brain MRI detection and quantification identifies regulated commercial products for brain volumetry, ARIA analysis and morphometric assessment, demonstrating that these applications are moving toward identifiable clinical software categories. Additional opportunities exist in vendor-neutral cloud deployment, multimodal MRI/PET analysis, CNS clinical trials, smaller hospitals that lack specialist neuroradiology resources, and emerging Asian markets where domestic medical-AI suppliers are building localized neuroimaging products.
Challenges
The principal long-term challenge is converting algorithmic performance into repeatable clinical and economic value. Regulatory clearance alone does not guarantee reimbursement, workflow adoption or sustained usage, and suppliers must continuously demonstrate reliability across diverse populations and imaging environments. Competitive intensity is also rising as specialized algorithms become integrated into larger enterprise-imaging, AI-orchestration and scanner-vendor ecosystems. Consolidation may increase access to distribution while simultaneously reducing the number of independent purchasing decisions available to smaller vendors. Data privacy requirements, cross-border cloud deployment rules, cybersecurity expectations and evolving AI regulation add further complexity. The market therefore favors companies that can combine validated algorithms with clinical integration, scalable deployment, regulatory execution and durable relationships with hospitals or pharmaceutical customers.
Value Chain Analysis
The Neuroimaging Software value chain begins with medical imaging data, computational infrastructure, image-processing frameworks, anatomical atlases, clinically annotated datasets and algorithm-development capabilities. These inputs support the development of segmentation, registration, volumetric analysis, perfusion modeling, diffusion analysis, functional mapping, molecular imaging quantification and AI-based detection tools. The midstream layer consists of specialized software companies, medical-imaging OEMs, clinical AI developers, nuclear-medicine software providers, neurosurgical planning vendors and CNS imaging platforms. Products are commercialized through perpetual or term licenses, enterprise subscriptions, SaaS contracts, per-scan or usage-based models, OEM embedding arrangements and clinical-trial contracts.
Value is created when raw imaging data are converted into quantitative measurements, biomarkers, workflow prioritization, treatment-planning information or longitudinal evidence that improves decision consistency and reduces manual analytical work. Downstream users include hospitals, imaging centers, neurology and neurosurgery departments, pharmaceutical and biotechnology companies, CROs and research institutions. Cost structures are dominated by software R&D, clinical validation, regulatory compliance, data acquisition and curation, cloud infrastructure, cybersecurity, integration, sales and implementation. As deployment moves toward recurring SaaS and enterprise models, scalable software economics become more important, but clinical support, integration and regulatory maintenance remain meaningful cost components.
Segment Insights
From a product-function perspective, the market contains several commercially meaningful segments rather than a single homogeneous software category. Acute stroke and neurovascular analysis is one of the most established clinical applications because software outputs can be integrated directly into time-sensitive emergency workflows. Advanced post-processing and visualization also represent an established installed-base segment through major imaging vendors. Quantitative brain MRI, neurodegenerative disease assessment and longitudinal biomarker analysis are gaining strategic importance as neurological treatment pathways increasingly require repeatable measurements rather than qualitative interpretation alone. MRI-related applications represent the broadest product coverage across the identified supplier universe, spanning structural volumetry, diffusion imaging, functional mapping, perfusion, multiple-sclerosis analysis and neuro-oncology.
The fastest-evolving opportunity set is concentrated around quantitative and treatment-linked applications rather than basic image viewing. Automated brain segmentation, hippocampal and regional volumetry, cortical and lesion measurement, ARIA assessment and longitudinal change analysis are becoming increasingly differentiated commercial functions. CMS documentation recognizes multiple FDA-cleared products addressing automated labeling, visualization and volumetric quantification of brain MRI, as well as dedicated ARIA analysis, supporting the emergence of a more defined regulated quantitative-neuroimaging segment. Functional MRI, DTI, tractography, connectomics and molecular neuroimaging remain smaller but technically differentiated segments with strong relevance in neurosurgery, research and CNS drug development.
Downstream Market Opportunities
Hospitals and diagnostic imaging centers remain the primary commercial users of Neuroimaging Software, but the demand profile is widening beyond the radiology department. Stroke centers require rapid neurovascular triage and perfusion analysis, neurology services increasingly use quantitative MRI for neurodegenerative and demyelinating diseases, and neurosurgical teams require multimodal fusion, tractography and functional mapping for preoperative planning. Pharmaceutical and biotechnology companies represent an increasingly strategic downstream opportunity because CNS drug programs depend on standardized longitudinal imaging biomarkers, patient stratification and safety monitoring. This creates room for software suppliers that can bridge routine clinical imaging and research-grade quantitative analysis. Smaller hospitals and imaging networks also represent an underpenetrated opportunity as cloud-based deployment reduces the need for dedicated local workstations and specialist post-processing resources.
Regional Insights
Europe has the largest concentration of identified independent specialist Neuroimaging Software suppliers, particularly in quantitative brain MRI, perfusion, nuclear medicine, functional imaging and neurodegenerative disease analysis. The region combines established medical-imaging technology clusters with a relatively broad base of smaller specialist developers. North America has a different competitive structure: major imaging and digital-health platforms coexist with commercially advanced stroke-AI, neurosurgical planning, quantitative imaging and research-software providers. The region remains particularly important for regulated clinical commercialization because FDA clearance, large hospital networks and pharmaceutical demand can support broader deployment of successful products. CMS activity around automated brain MRI quantification also highlights increasing attention to the clinical and reimbursement framework for quantitative neuroimaging.
Asia-Pacific is becoming more strategically important but remains structurally fragmented. Japan combines global imaging OEMs with domestic neurological AI developers, while South Korea has developed a relatively dense cluster of specialist brain-imaging AI companies focused on volumetry, stroke, Parkinson’s disease, intracranial hemorrhage and cerebrovascular analysis. China has a growing medical-AI ecosystem, although the stricter product-evidence standard applied in this study results in a smaller Core Formal List than in Europe or North America. Taiwan and Australia contribute several niche vendors in diffusion MRI, brain metastasis analysis, perfusion and quantitative neuroimaging. The regional opportunity therefore lies less in simple geographic expansion and more in localization, regulatory approval, hospital integration and adaptation to country-specific clinical workflows.
Competitive Landscape Analysis
The Neuroimaging Software market has a layered competitive structure rather than a single group of directly comparable competitors. Major imaging OEMs compete through scanner installed bases, integrated workstations, enterprise-imaging relationships and global distribution, while independent specialists compete through deeper algorithms and clinical focus in stroke, brain volumetry, neurodegeneration, perfusion, molecular imaging, fMRI/DTI, neuro-oncology and neurosurgical planning. The study identifies 61 companies in the Core Formal List, demonstrating that the commercially relevant supplier base extends well beyond a small group of global imaging companies. Competitive consolidation is increasing as larger platforms acquire specialized software capabilities. GE HealthCare closed its acquisition of icometrix in 2025 to strengthen neurological MRI analysis, SyntheticMR acquired Combinostics to broaden quantitative neuroimaging capabilities, and RadNet acquired Gleamer in 2026 to expand DeepHealth’s clinical AI portfolio. These transactions point toward continued integration of specialist algorithms into broader imaging ecosystems, but highly differentiated areas such as ARIA quantification, connectomics, advanced perfusion, molecular imaging and functional brain mapping continue to provide defensible positions for focused vendors.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Neuroimaging Software market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GE HealthCare
Siemens Healthineers
RapidAI
Viz.ai
Philips
Brainlab
Canon
Fujifilm
Brainomix
Bruker
Cortechs.ai
RadNet
Aidoc
ConcertAI
Qure.ai
United Imaging Intelligence
Shukun Technology
Infervision
Stryker
Nicolab
Avicenna.AI
Synaptive Medical
Quibim
Surgical Theater
mediaire
Qynapse
Thermo Fisher
Hermes Medical Solutions
Omniscient Neurotechnology
IQ-AI
Neurophet
LPIXEL
JLK
Brainreader
NordicNeuroLab
VUNO
Heuron
Coreline Soft
Cercare Medical
Segment by Type
Advanced Post-processing and Visualization
Quantitative Biomarkers and Volumetry
AI Detection
Molecular Neuroimaging Quantification
Others
Segment by Deployment Model
On-premise
Cloud-based
Hybrid
Segment by Intended Use
Clinical Diagnostic or Decision Support
Clinical Trial or Drug Development
Research Use Only
Others
Segment by Application
Stroke and Cerebrovascular Disease
Neurodegenerative Disease and Multiple Sclerosis
Neuro-oncology
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Neuroimaging Software study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Neuroimaging Software: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Neuroimaging Software Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Advanced Post-processing and Visualization
1.2.3 Quantitative Biomarkers and Volumetry
1.2.4 AI Detection
1.2.5 Molecular Neuroimaging Quantification
1.2.6 Others
1.3 Market Segmentation by Deployment Model
1.3.1 Global Neuroimaging Software Market Size by Deployment Model, 2021 vs 2025 vs 2032
1.3.2 On-premise
1.3.3 Cloud-based
1.3.4 Hybrid
1.4 Market Segmentation by Intended Use
1.4.1 Global Neuroimaging Software Market Size by Intended Use, 2021 vs 2025 vs 2032
1.4.2 Clinical Diagnostic or Decision Support
1.4.3 Clinical Trial or Drug Development
1.4.4 Research Use Only
1.4.5 Others
1.5 Market Segmentation by Application
1.5.1 Global Neuroimaging Software Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Stroke and Cerebrovascular Disease
1.5.3 Neurodegenerative Disease and Multiple Sclerosis
1.5.4 Neuro-oncology
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Neuroimaging Software Revenue Estimates and Forecasts (2021-2032)
2.2 Global Neuroimaging Software Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Neuroimaging Software Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Neuroimaging Software Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Advanced Post-processing and Visualization: Market Share by Key Players
3.3.2 Quantitative Biomarkers and Volumetry: Market Share by Key Players
3.3.3 AI Detection: Market Share by Key Players
3.3.4 Molecular Neuroimaging Quantification: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Neuroimaging Software Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Neuroimaging Software Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Neuroimaging Software Market by Deployment Model
4.2.1 Global Revenue by Deployment Model (2021-2032)
4.2.2 Global Revenue-Based Market Share by Deployment Model (2021-2032)
4.3 Global Neuroimaging Software Market by Intended Use
4.3.1 Global Revenue by Intended Use (2021-2032)
4.3.2 Global Revenue-Based Market Share by Intended Use (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Neuroimaging Software Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Neuroimaging Software Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Neuroimaging Software Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Neuroimaging Software Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Neuroimaging Software Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Neuroimaging Software Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Neuroimaging Software Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Neuroimaging Software Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Neuroimaging Software Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Neuroimaging Software Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Neuroimaging Software Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 GE HealthCare
11.1.1 GE HealthCare Corporation Information
11.1.2 GE HealthCare Business Overview
11.1.3 GE HealthCare Neuroimaging Software Product Features and Attributes
11.1.4 GE HealthCare Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.1.5 GE HealthCare Neuroimaging Software Revenue by Product in 2025
11.1.6 GE HealthCare Neuroimaging Software Revenue by Application in 2025
11.1.7 GE HealthCare Neuroimaging Software Revenue by Geographic Area in 2025
11.1.8 GE HealthCare Neuroimaging Software SWOT Analysis
11.1.9 GE HealthCare Recent Developments
11.2 Siemens Healthineers
11.2.1 Siemens Healthineers Corporation Information
11.2.2 Siemens Healthineers Business Overview
11.2.3 Siemens Healthineers Neuroimaging Software Product Features and Attributes
11.2.4 Siemens Healthineers Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.2.5 Siemens Healthineers Neuroimaging Software Revenue by Product in 2025
11.2.6 Siemens Healthineers Neuroimaging Software Revenue by Application in 2025
11.2.7 Siemens Healthineers Neuroimaging Software Revenue by Geographic Area in 2025
11.2.8 Siemens Healthineers Neuroimaging Software SWOT Analysis
11.2.9 Siemens Healthineers Recent Developments
11.3 RapidAI
11.3.1 RapidAI Corporation Information
11.3.2 RapidAI Business Overview
11.3.3 RapidAI Neuroimaging Software Product Features and Attributes
11.3.4 RapidAI Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.3.5 RapidAI Neuroimaging Software Revenue by Product in 2025
11.3.6 RapidAI Neuroimaging Software Revenue by Application in 2025
11.3.7 RapidAI Neuroimaging Software Revenue by Geographic Area in 2025
11.3.8 RapidAI Neuroimaging Software SWOT Analysis
11.3.9 RapidAI Recent Developments
11.4 Viz.ai
11.4.1 Viz.ai Corporation Information
11.4.2 Viz.ai Business Overview
11.4.3 Viz.ai Neuroimaging Software Product Features and Attributes
11.4.4 Viz.ai Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.4.5 Viz.ai Neuroimaging Software Revenue by Product in 2025
11.4.6 Viz.ai Neuroimaging Software Revenue by Application in 2025
11.4.7 Viz.ai Neuroimaging Software Revenue by Geographic Area in 2025
11.4.8 Viz.ai Neuroimaging Software SWOT Analysis
11.4.9 Viz.ai Recent Developments
11.5 Philips
11.5.1 Philips Corporation Information
11.5.2 Philips Business Overview
11.5.3 Philips Neuroimaging Software Product Features and Attributes
11.5.4 Philips Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.5.5 Philips Neuroimaging Software Revenue by Product in 2025
11.5.6 Philips Neuroimaging Software Revenue by Application in 2025
11.5.7 Philips Neuroimaging Software Revenue by Geographic Area in 2025
11.5.8 Philips Neuroimaging Software SWOT Analysis
11.5.9 Philips Recent Developments
11.6 Brainlab
11.6.1 Brainlab Corporation Information
11.6.2 Brainlab Business Overview
11.6.3 Brainlab Neuroimaging Software Product Features and Attributes
11.6.4 Brainlab Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.6.5 Brainlab Recent Developments
11.7 Canon
11.7.1 Canon Corporation Information
11.7.2 Canon Business Overview
11.7.3 Canon Neuroimaging Software Product Features and Attributes
11.7.4 Canon Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.7.5 Canon Recent Developments
11.8 Fujifilm
11.8.1 Fujifilm Corporation Information
11.8.2 Fujifilm Business Overview
11.8.3 Fujifilm Neuroimaging Software Product Features and Attributes
11.8.4 Fujifilm Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.8.5 Fujifilm Recent Developments
11.9 Brainomix
11.9.1 Brainomix Corporation Information
11.9.2 Brainomix Business Overview
11.9.3 Brainomix Neuroimaging Software Product Features and Attributes
11.9.4 Brainomix Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.9.5 Brainomix Recent Developments
11.10 Bruker
11.10.1 Bruker Corporation Information
11.10.2 Bruker Business Overview
11.10.3 Bruker Neuroimaging Software Product Features and Attributes
11.10.4 Bruker Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Cortechs.ai
11.11.1 Cortechs.ai Corporation Information
11.11.2 Cortechs.ai Business Overview
11.11.3 Cortechs.ai Neuroimaging Software Product Features and Attributes
11.11.4 Cortechs.ai Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.11.5 Cortechs.ai Recent Developments
11.12 RadNet
11.12.1 RadNet Corporation Information
11.12.2 RadNet Business Overview
11.12.3 RadNet Neuroimaging Software Product Features and Attributes
11.12.4 RadNet Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.12.5 RadNet Recent Developments
11.13 Aidoc
11.13.1 Aidoc Corporation Information
11.13.2 Aidoc Business Overview
11.13.3 Aidoc Neuroimaging Software Product Features and Attributes
11.13.4 Aidoc Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.13.5 Aidoc Recent Developments
11.14 ConcertAI
11.14.1 ConcertAI Corporation Information
11.14.2 ConcertAI Business Overview
11.14.3 ConcertAI Neuroimaging Software Product Features and Attributes
11.14.4 ConcertAI Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.14.5 ConcertAI Recent Developments
11.15 Qure.ai
11.15.1 Qure.ai Corporation Information
11.15.2 Qure.ai Business Overview
11.15.3 Qure.ai Neuroimaging Software Product Features and Attributes
11.15.4 Qure.ai Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.15.5 Qure.ai Recent Developments
11.16 United Imaging Intelligence
11.16.1 United Imaging Intelligence Corporation Information
11.16.2 United Imaging Intelligence Business Overview
11.16.3 United Imaging Intelligence Neuroimaging Software Product Features and Attributes
11.16.4 United Imaging Intelligence Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.16.5 United Imaging Intelligence Recent Developments
11.17 Shukun Technology
11.17.1 Shukun Technology Corporation Information
11.17.2 Shukun Technology Business Overview
11.17.3 Shukun Technology Neuroimaging Software Product Features and Attributes
11.17.4 Shukun Technology Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.17.5 Shukun Technology Recent Developments
11.18 Infervision
11.18.1 Infervision Corporation Information
11.18.2 Infervision Business Overview
11.18.3 Infervision Neuroimaging Software Product Features and Attributes
11.18.4 Infervision Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.18.5 Infervision Recent Developments
11.19 Stryker
11.19.1 Stryker Corporation Information
11.19.2 Stryker Business Overview
11.19.3 Stryker Neuroimaging Software Product Features and Attributes
11.19.4 Stryker Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.19.5 Stryker Recent Developments
11.20 Nicolab
11.20.1 Nicolab Corporation Information
11.20.2 Nicolab Business Overview
11.20.3 Nicolab Neuroimaging Software Product Features and Attributes
11.20.4 Nicolab Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.20.5 Nicolab Recent Developments
11.21 Avicenna.AI
11.21.1 Avicenna.AI Corporation Information
11.21.2 Avicenna.AI Business Overview
11.21.3 Avicenna.AI Neuroimaging Software Product Features and Attributes
11.21.4 Avicenna.AI Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.21.5 Avicenna.AI Recent Developments
11.22 Synaptive Medical
11.22.1 Synaptive Medical Corporation Information
11.22.2 Synaptive Medical Business Overview
11.22.3 Synaptive Medical Neuroimaging Software Product Features and Attributes
11.22.4 Synaptive Medical Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.22.5 Synaptive Medical Recent Developments
11.23 Quibim
11.23.1 Quibim Corporation Information
11.23.2 Quibim Business Overview
11.23.3 Quibim Neuroimaging Software Product Features and Attributes
11.23.4 Quibim Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.23.5 Quibim Recent Developments
11.24 Surgical Theater
11.24.1 Surgical Theater Corporation Information
11.24.2 Surgical Theater Business Overview
11.24.3 Surgical Theater Neuroimaging Software Product Features and Attributes
11.24.4 Surgical Theater Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.24.5 Surgical Theater Recent Developments
11.25 mediaire
11.25.1 mediaire Corporation Information
11.25.2 mediaire Business Overview
11.25.3 mediaire Neuroimaging Software Product Features and Attributes
11.25.4 mediaire Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.25.5 mediaire Recent Developments
11.26 Qynapse
11.26.1 Qynapse Corporation Information
11.26.2 Qynapse Business Overview
11.26.3 Qynapse Neuroimaging Software Product Features and Attributes
11.26.4 Qynapse Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.26.5 Qynapse Recent Developments
11.27 Thermo Fisher
11.27.1 Thermo Fisher Corporation Information
11.27.2 Thermo Fisher Business Overview
11.27.3 Thermo Fisher Neuroimaging Software Product Features and Attributes
11.27.4 Thermo Fisher Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.27.5 Thermo Fisher Recent Developments
11.28 Hermes Medical Solutions
11.28.1 Hermes Medical Solutions Corporation Information
11.28.2 Hermes Medical Solutions Business Overview
11.28.3 Hermes Medical Solutions Neuroimaging Software Product Features and Attributes
11.28.4 Hermes Medical Solutions Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.28.5 Hermes Medical Solutions Recent Developments
11.29 Omniscient Neurotechnology
11.29.1 Omniscient Neurotechnology Corporation Information
11.29.2 Omniscient Neurotechnology Business Overview
11.29.3 Omniscient Neurotechnology Neuroimaging Software Product Features and Attributes
11.29.4 Omniscient Neurotechnology Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.29.5 Omniscient Neurotechnology Recent Developments
11.30 IQ-AI
11.30.1 IQ-AI Corporation Information
11.30.2 IQ-AI Business Overview
11.30.3 IQ-AI Neuroimaging Software Product Features and Attributes
11.30.4 IQ-AI Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.30.5 IQ-AI Recent Developments
11.31 Neurophet
11.31.1 Neurophet Corporation Information
11.31.2 Neurophet Business Overview
11.31.3 Neurophet Neuroimaging Software Product Features and Attributes
11.31.4 Neurophet Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.31.5 Neurophet Recent Developments
11.32 LPIXEL
11.32.1 LPIXEL Corporation Information
11.32.2 LPIXEL Business Overview
11.32.3 LPIXEL Neuroimaging Software Product Features and Attributes
11.32.4 LPIXEL Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.32.5 LPIXEL Recent Developments
11.33 JLK
11.33.1 JLK Corporation Information
11.33.2 JLK Business Overview
11.33.3 JLK Neuroimaging Software Product Features and Attributes
11.33.4 JLK Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.33.5 JLK Recent Developments
11.34 Brainreader
11.34.1 Brainreader Corporation Information
11.34.2 Brainreader Business Overview
11.34.3 Brainreader Neuroimaging Software Product Features and Attributes
11.34.4 Brainreader Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.34.5 Brainreader Recent Developments
11.35 NordicNeuroLab
11.35.1 NordicNeuroLab Corporation Information
11.35.2 NordicNeuroLab Business Overview
11.35.3 NordicNeuroLab Neuroimaging Software Product Features and Attributes
11.35.4 NordicNeuroLab Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.35.5 NordicNeuroLab Recent Developments
11.36 VUNO
11.36.1 VUNO Corporation Information
11.36.2 VUNO Business Overview
11.36.3 VUNO Neuroimaging Software Product Features and Attributes
11.36.4 VUNO Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.36.5 VUNO Recent Developments
11.37 Heuron
11.37.1 Heuron Corporation Information
11.37.2 Heuron Business Overview
11.37.3 Heuron Neuroimaging Software Product Features and Attributes
11.37.4 Heuron Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.37.5 Heuron Recent Developments
11.38 Coreline Soft
11.38.1 Coreline Soft Corporation Information
11.38.2 Coreline Soft Business Overview
11.38.3 Coreline Soft Neuroimaging Software Product Features and Attributes
11.38.4 Coreline Soft Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.38.5 Coreline Soft Recent Developments
11.39 Cercare Medical
11.39.1 Cercare Medical Corporation Information
11.39.2 Cercare Medical Business Overview
11.39.3 Cercare Medical Neuroimaging Software Product Features and Attributes
11.39.4 Cercare Medical Neuroimaging Software Revenue and Gross Margin (2021-2026)
11.39.5 Cercare Medical Recent Developments
12 Neuroimaging Software Value Chain and Ecosystem Analysis
12.1 Neuroimaging Software Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Neuroimaging Software Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Neuroimaging Software Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Neuroimaging Software Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Neuroimaging Software Market Size Growth Rate by Deployment Model, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Neuroimaging Software Market Size Growth Rate by Intended Use, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Neuroimaging Software Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Neuroimaging Software Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Neuroimaging Software Revenue by Region (US$ Million), 2021-2026
Table 7. Global Neuroimaging Software Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Neuroimaging Software Revenue by Players (US$ Million), 2021-2026
Table 10. Global Neuroimaging Software Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Neuroimaging Software Revenue, 2025
Table 13. Global Neuroimaging Software Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Neuroimaging Software Companies Headquarters
Table 15. Global Neuroimaging Software Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Neuroimaging Software Revenue by Type (US$ Million), 2021-2026
Table 19. Global Neuroimaging Software Revenue by Type (US$ Million), 2027-2032
Table 20. Global Neuroimaging Software Revenue by Deployment Model (US$ Million), 2021-2026
Table 21. Global Neuroimaging Software Revenue by Deployment Model (US$ Million), 2027-2032
Table 22. Global Neuroimaging Software Revenue by Intended Use (US$ Million), 2021-2026
Table 23. Global Neuroimaging Software Revenue by Intended Use (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Neuroimaging Software Revenue by Application (US$ Million), 2021-2026
Table 26. Global Neuroimaging Software Revenue by Application (US$ Million), 2027-2032
Table 27. Neuroimaging Software High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Neuroimaging Software Growth Accelerators and Market Barriers
Table 31. North America Neuroimaging Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Neuroimaging Software Growth Accelerators and Market Barriers
Table 33. Europe Neuroimaging Software Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Neuroimaging Software Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Neuroimaging Software Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Neuroimaging Software Investment Opportunities and Key Challenges
Table 37. Central and South America Neuroimaging Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Neuroimaging Software Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Neuroimaging Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. GE HealthCare Corporation Information
Table 41. GE HealthCare Description and Major Businesses
Table 42. GE HealthCare Product Features and Attributes
Table 43. GE HealthCare Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. GE HealthCare Revenue Proportion by Product in 2025
Table 45. GE HealthCare Revenue Proportion by Application in 2025
Table 46. GE HealthCare Revenue Proportion by Geographic Area in 2025
Table 47. GE HealthCare Neuroimaging Software SWOT Analysis
Table 48. GE HealthCare Recent Developments
Table 49. Siemens Healthineers Corporation Information
Table 50. Siemens Healthineers Description and Major Businesses
Table 51. Siemens Healthineers Product Features and Attributes
Table 52. Siemens Healthineers Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Siemens Healthineers Revenue Proportion by Product in 2025
Table 54. Siemens Healthineers Revenue Proportion by Application in 2025
Table 55. Siemens Healthineers Revenue Proportion by Geographic Area in 2025
Table 56. Siemens Healthineers Neuroimaging Software SWOT Analysis
Table 57. Siemens Healthineers Recent Developments
Table 58. RapidAI Corporation Information
Table 59. RapidAI Description and Major Businesses
Table 60. RapidAI Product Features and Attributes
Table 61. RapidAI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. RapidAI Revenue Proportion by Product in 2025
Table 63. RapidAI Revenue Proportion by Application in 2025
Table 64. RapidAI Revenue Proportion by Geographic Area in 2025
Table 65. RapidAI Neuroimaging Software SWOT Analysis
Table 66. RapidAI Recent Developments
Table 67. Viz.ai Corporation Information
Table 68. Viz.ai Description and Major Businesses
Table 69. Viz.ai Product Features and Attributes
Table 70. Viz.ai Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Viz.ai Revenue Proportion by Product in 2025
Table 72. Viz.ai Revenue Proportion by Application in 2025
Table 73. Viz.ai Revenue Proportion by Geographic Area in 2025
Table 74. Viz.ai Neuroimaging Software SWOT Analysis
Table 75. Viz.ai Recent Developments
Table 76. Philips Corporation Information
Table 77. Philips Description and Major Businesses
Table 78. Philips Product Features and Attributes
Table 79. Philips Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Philips Revenue Proportion by Product in 2025
Table 81. Philips Revenue Proportion by Application in 2025
Table 82. Philips Revenue Proportion by Geographic Area in 2025
Table 83. Philips Neuroimaging Software SWOT Analysis
Table 84. Philips Recent Developments
Table 85. Brainlab Corporation Information
Table 86. Brainlab Description and Major Businesses
Table 87. Brainlab Product Features and Attributes
Table 88. Brainlab Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Brainlab Recent Developments
Table 90. Canon Corporation Information
Table 91. Canon Description and Major Businesses
Table 92. Canon Product Features and Attributes
Table 93. Canon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Canon Recent Developments
Table 95. Fujifilm Corporation Information
Table 96. Fujifilm Description and Major Businesses
Table 97. Fujifilm Product Features and Attributes
Table 98. Fujifilm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Fujifilm Recent Developments
Table 100. Brainomix Corporation Information
Table 101. Brainomix Description and Major Businesses
Table 102. Brainomix Product Features and Attributes
Table 103. Brainomix Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Brainomix Recent Developments
Table 105. Bruker Corporation Information
Table 106. Bruker Description and Major Businesses
Table 107. Bruker Product Features and Attributes
Table 108. Bruker Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Bruker Recent Developments
Table 110. Cortechs.ai Corporation Information
Table 111. Cortechs.ai Description and Major Businesses
Table 112. Cortechs.ai Product Features and Attributes
Table 113. Cortechs.ai Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Cortechs.ai Recent Developments
Table 115. RadNet Corporation Information
Table 116. RadNet Description and Major Businesses
Table 117. RadNet Product Features and Attributes
Table 118. RadNet Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. RadNet Recent Developments
Table 120. Aidoc Corporation Information
Table 121. Aidoc Description and Major Businesses
Table 122. Aidoc Product Features and Attributes
Table 123. Aidoc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Aidoc Recent Developments
Table 125. ConcertAI Corporation Information
Table 126. ConcertAI Description and Major Businesses
Table 127. ConcertAI Product Features and Attributes
Table 128. ConcertAI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. ConcertAI Recent Developments
Table 130. Qure.ai Corporation Information
Table 131. Qure.ai Description and Major Businesses
Table 132. Qure.ai Product Features and Attributes
Table 133. Qure.ai Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Qure.ai Recent Developments
Table 135. United Imaging Intelligence Corporation Information
Table 136. United Imaging Intelligence Description and Major Businesses
Table 137. United Imaging Intelligence Product Features and Attributes
Table 138. United Imaging Intelligence Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. United Imaging Intelligence Recent Developments
Table 140. Shukun Technology Corporation Information
Table 141. Shukun Technology Description and Major Businesses
Table 142. Shukun Technology Product Features and Attributes
Table 143. Shukun Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Shukun Technology Recent Developments
Table 145. Infervision Corporation Information
Table 146. Infervision Description and Major Businesses
Table 147. Infervision Product Features and Attributes
Table 148. Infervision Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Infervision Recent Developments
Table 150. Stryker Corporation Information
Table 151. Stryker Description and Major Businesses
Table 152. Stryker Product Features and Attributes
Table 153. Stryker Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Stryker Recent Developments
Table 155. Nicolab Corporation Information
Table 156. Nicolab Description and Major Businesses
Table 157. Nicolab Product Features and Attributes
Table 158. Nicolab Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Nicolab Recent Developments
Table 160. Avicenna.AI Corporation Information
Table 161. Avicenna.AI Description and Major Businesses
Table 162. Avicenna.AI Product Features and Attributes
Table 163. Avicenna.AI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Avicenna.AI Recent Developments
Table 165. Synaptive Medical Corporation Information
Table 166. Synaptive Medical Description and Major Businesses
Table 167. Synaptive Medical Product Features and Attributes
Table 168. Synaptive Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Synaptive Medical Recent Developments
Table 170. Quibim Corporation Information
Table 171. Quibim Description and Major Businesses
Table 172. Quibim Product Features and Attributes
Table 173. Quibim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Quibim Recent Developments
Table 175. Surgical Theater Corporation Information
Table 176. Surgical Theater Description and Major Businesses
Table 177. Surgical Theater Product Features and Attributes
Table 178. Surgical Theater Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Surgical Theater Recent Developments
Table 180. mediaire Corporation Information
Table 181. mediaire Description and Major Businesses
Table 182. mediaire Product Features and Attributes
Table 183. mediaire Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. mediaire Recent Developments
Table 185. Qynapse Corporation Information
Table 186. Qynapse Description and Major Businesses
Table 187. Qynapse Product Features and Attributes
Table 188. Qynapse Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Qynapse Recent Developments
Table 190. Thermo Fisher Corporation Information
Table 191. Thermo Fisher Description and Major Businesses
Table 192. Thermo Fisher Product Features and Attributes
Table 193. Thermo Fisher Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Thermo Fisher Recent Developments
Table 195. Hermes Medical Solutions Corporation Information
Table 196. Hermes Medical Solutions Description and Major Businesses
Table 197. Hermes Medical Solutions Product Features and Attributes
Table 198. Hermes Medical Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Hermes Medical Solutions Recent Developments
Table 200. Omniscient Neurotechnology Corporation Information
Table 201. Omniscient Neurotechnology Description and Major Businesses
Table 202. Omniscient Neurotechnology Product Features and Attributes
Table 203. Omniscient Neurotechnology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Omniscient Neurotechnology Recent Developments
Table 205. IQ-AI Corporation Information
Table 206. IQ-AI Description and Major Businesses
Table 207. IQ-AI Product Features and Attributes
Table 208. IQ-AI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. IQ-AI Recent Developments
Table 210. Neurophet Corporation Information
Table 211. Neurophet Description and Major Businesses
Table 212. Neurophet Product Features and Attributes
Table 213. Neurophet Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Neurophet Recent Developments
Table 215. LPIXEL Corporation Information
Table 216. LPIXEL Description and Major Businesses
Table 217. LPIXEL Product Features and Attributes
Table 218. LPIXEL Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. LPIXEL Recent Developments
Table 220. JLK Corporation Information
Table 221. JLK Description and Major Businesses
Table 222. JLK Product Features and Attributes
Table 223. JLK Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. JLK Recent Developments
Table 225. Brainreader Corporation Information
Table 226. Brainreader Description and Major Businesses
Table 227. Brainreader Product Features and Attributes
Table 228. Brainreader Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Brainreader Recent Developments
Table 230. NordicNeuroLab Corporation Information
Table 231. NordicNeuroLab Description and Major Businesses
Table 232. NordicNeuroLab Product Features and Attributes
Table 233. NordicNeuroLab Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. NordicNeuroLab Recent Developments
Table 235. VUNO Corporation Information
Table 236. VUNO Description and Major Businesses
Table 237. VUNO Product Features and Attributes
Table 238. VUNO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. VUNO Recent Developments
Table 240. Heuron Corporation Information
Table 241. Heuron Description and Major Businesses
Table 242. Heuron Product Features and Attributes
Table 243. Heuron Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. Heuron Recent Developments
Table 245. Coreline Soft Corporation Information
Table 246. Coreline Soft Description and Major Businesses
Table 247. Coreline Soft Product Features and Attributes
Table 248. Coreline Soft Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Coreline Soft Recent Developments
Table 250. Cercare Medical Corporation Information
Table 251. Cercare Medical Description and Major Businesses
Table 252. Cercare Medical Product Features and Attributes
Table 253. Cercare Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Cercare Medical Recent Developments
Table 255. Technologies, Platforms and Infrastructure
Table 256. Distributors List
Table 257. Market Trends and Market Evolution
Table 258. Market Drivers and Opportunities
Table 259. Market Challenges, Risks, and Restraints
Table 260. Research Programs/Design for This Report
Table 261. Key Data Information from Secondary Sources
Table 262. Key Data Information from Primary Sources


List of Figures
Figure 1. Global Neuroimaging Software Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Advanced Post-processing and Visualization Product Picture
Figure 3. Quantitative Biomarkers and Volumetry Product Picture
Figure 4. AI Detection Product Picture
Figure 5. Molecular Neuroimaging Quantification Product Picture
Figure 6. Others Product Picture
Figure 7. Global Neuroimaging Software Market Size Growth Rate by Deployment Model, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. On-premise Product Picture
Figure 9. Cloud-based Product Picture
Figure 10. Hybrid Product Picture
Figure 11. Global Neuroimaging Software Market Size Growth Rate by Intended Use, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Clinical Diagnostic or Decision Support Product Picture
Figure 13. Clinical Trial or Drug Development Product Picture
Figure 14. Research Use Only Product Picture
Figure 15. Others Product Picture
Figure 16. Global Neuroimaging Software Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 17. Stroke and Cerebrovascular Disease
Figure 18. Neurodegenerative Disease and Multiple Sclerosis
Figure 19. Neuro-oncology
Figure 20. Others
Figure 21. Neuroimaging Software Report Years Considered
Figure 22. Global Neuroimaging Software Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 24. Global Neuroimaging Software Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Neuroimaging Software Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Neuroimaging Software Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Advanced Post-processing and Visualization Revenue-Based Market Share by Player in 2025
Figure 29. Quantitative Biomarkers and Volumetry Revenue-Based Market Share by Player in 2025
Figure 30. AI Detection Revenue-Based Market Share by Player in 2025
Figure 31. Molecular Neuroimaging Quantification Revenue-Based Market Share by Player in 2025
Figure 32. Others Revenue-Based Market Share by Player in 2025
Figure 33. Global Neuroimaging Software Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Neuroimaging Software Revenue-Based Market Share by Deployment Model (2021-2032)
Figure 35. Global Neuroimaging Software Revenue-Based Market Share by Intended Use (2021-2032)
Figure 36. Global Neuroimaging Software Revenue-Based Market Share by Application (2021-2032)
Figure 37. North America Neuroimaging Software Revenue YoY (US$ Million), 2021-2032
Figure 38. North America Top 5 Players Neuroimaging Software Revenue (US$ Million) in 2025
Figure 39. North America Neuroimaging Software Revenue (US$ Million) by Application (2021-2032)
Figure 40. US Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 41. Canada Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 42. Mexico Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 43. Europe Neuroimaging Software Revenue YoY (US$ Million), 2021-2032
Figure 44. Europe Top 5 Players Neuroimaging Software Revenue (US$ Million) in 2025
Figure 45. Europe Neuroimaging Software Revenue (US$ Million) by Application (2021-2032)
Figure 46. Germany Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 47. France Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 48. U.K. Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 49. Italy Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 50. Russia Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 51. Asia-Pacific Neuroimaging Software Revenue YoY (US$ Million), 2021-2032
Figure 52. Asia-Pacific Top 8 Players Neuroimaging Software Revenue (US$ Million) in 2025
Figure 53. Asia-Pacific Neuroimaging Software Revenue (US$ Million) by Application (2021-2032)
Figure 54. Indonesia Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 55. Japan Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 56. South Korea Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 57. Australia Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 58. India Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 59. Indonesia Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 60. Vietnam Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 61. Malaysia Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 62. Philippines Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 63. Singapore Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 64. Central and South America Neuroimaging Software Revenue YoY (US$ Million), 2021-2032
Figure 65. Central and South America Top 5 Players Neuroimaging Software Revenue (US$ Million) in 2025
Figure 66. Central and South America Neuroimaging Software Revenue (US$ Million) by Application (2021-2032)
Figure 67. Brazil Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 68. Argentina Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 69. Middle East and Africa Neuroimaging Software Revenue YoY (US$ Million), 2021-2032
Figure 70. Middle East and Africa Top 5 Players Neuroimaging Software Revenue (US$ Million) in 2025
Figure 71. Middle East and Africa Neuroimaging Software Revenue (US$ Million) by Application (2021-2032)
Figure 72. GCC Countries Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 73. Israel Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 74. Egypt Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 75. South Africa Neuroimaging Software Revenue (US$ Million), 2021-2032
Figure 76. Neuroimaging Software Value Chain Mapping
Figure 77. Channels of Distribution (Direct Vs Distribution)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed